Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib and Atezolizumab in Advanced Rare Tumors
NCT03108131Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2017
- Primary completion
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cobimetinib and atezolizumab in skin squamous cell carcinoma (SCC), appendiceal adenocarcinoma and Adenocarcinoma of the small intestine (SBA), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate up to 3 years. Started Apr 2017; status: completed.
02
Drugs
cobimetinibatezolizumab
03
Conditions
skin squamous cell carcinoma (SCC)appendiceal adenocarcinomaAdenocarcinoma of the small intestine (SBA)
Beyond the preview
Go deeper on NCT03108131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108131.